Ishares Nasdaq Biotechnology (IBB) Buy, Sell…

Ishares Nasdaq Biotechnology (IBB)

173.44

+2.00 (1.17%)

as of Jun 17, 2026, 8:00:00 pm Market Open.

66 watching

BUY

He likes big pharma with AbbVie his favourite name. Pipelines are starting to fill, and if rates hold and R&D gets cheaper, these stocks will continue to work.

BUY

He prefers to own individual names, but you need to own biotech, especially if there's a change in Washington (less regulation). It's very sensitive to interest rates, which will likely decline.

BUY

The sector has been up. It makes sense because biotechs do well as rates fall; these companies finance long-duration trials then marketing.

HOLD

He bought this, expecting biotech to break out, but it's been deeply disappointing. It hasn't worked yet.

BUY

The IBB has never had two down years in a row, except this and last year. It's having its best month since June 2021.

BUY

He likes biotech, focusing on longevity research. Better than owning a single biotech stock where you can lose 80% just on negative research findings. It's completely random--you have no idea what the outcome will be on these biotech products. Might as well own IBB and lessen risk.

WATCH

He sold IBB last month, though he owns a lot of Regeneron (for its fundamentals) in the biotech space. You need to own individual names, not the macro in biotechs. But he could re-enter IBB when the time is right.

DON'T BUY

IBB vs. XLV XLV has done very well, and also well positioned for the type of market we're in right now. Cap weighted. A fine way to get pure beta in the sector. A better choice than IBB. IBB is much more concentrated with a higher risk in biotech. Smaller caps have lagged large caps since last year, to the tune of 50-60% relative performance, because of the impact of higher interest rates on growth, plus the FDA's become slower to approve new drugs.

BUY ON WEAKNESS

IBB gives him exposure to Moderna, its largest holding, and yet there's no single-company risk here. Biotechs have been under a lot of pressure this year, so he sees an opportunity (past of the pressure has been from shorting) if you're patient. He likes the future of biotech.

PAST TOP PICK

(A Top Pick Jul 09/20, Up 14%) Still likes it, but took profits as the valuation was getting expensive, plus the shift from growth to value. Long term, lots of tailwinds.

PAST TOP PICK

(A Top Pick Jul 09/20, Up 6%) Sold in February, as he saw the writing on the wall with the rotation away from growth. Not cheap at 28x. Long-term, makes a lot of sense. Aging population, growing middle class in emerging markets will keep demand up.

BUY

Healthcare sector outlook The sector has had a great bounce since March lows. A good way to play the COVID vaccine race. IBB is the best-known biotech ETF, but he does the XBI, because it's equal-weighted. XBI has had a great bounce. It's a great sector with reasonable valuations. The race for a COVID vaccine is a tailwind, of course. Biotech is a slow-growth area, which benefit from interest rates staying very low for the long term.

TOP PICK

Growth of biotech is expected to explode in a post-pandemic world. Longer term, aging population and growth of middle class are tailwinds. 27 bps expense ratio. Yield is 0.22%.

HOLD

A very good biotech ETF. If you have it and you like it, stay with it. See what percentage of your portfolio it comprises. For a sector play, don't go above 5-6% of your portfolio. You want to invest in it, not day trade it with every move.

PAST TOP PICK

(A Top Pick May 06/19, Down 6%) What did not happen this year was there was not the usual seasonal uptick in June. A long term hold. He thinks biotech is the next wave that drives markets for the next generation. Everyone should own biotech in their portfolio.

Showing 1 to 15 of 77 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Ishares Nasdaq Biotechnology (IBB) Frequently Asked Questions

What is Ishares Nasdaq Biotechnology stock symbol?

Ishares Nasdaq Biotechnology is a American stock, trading under the symbol IBB (previously IBB-Q on Stockchase) on the NASDAQ (IBB). It is usually referred to as NASDAQ:IBB or IBB

Is Ishares Nasdaq Biotechnology a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on IBB (previously IBB-Q on Stockchase) on Stockchase. Read the latest expert commentary for Ishares Nasdaq Biotechnology.

Is Ishares Nasdaq Biotechnology a good investment or a top pick?

Ishares Nasdaq Biotechnology was recommended as a Top Pick by Hap (Robert) Sneddon FCSI on 2019-10-18. Read the latest stock experts ratings for Ishares Nasdaq Biotechnology.

Why is Ishares Nasdaq Biotechnology stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Ishares Nasdaq Biotechnology.

Is Ishares Nasdaq Biotechnology worth watching?

Ishares Nasdaq Biotechnology is followed by 66 investors on Stockchase and is a trending stock that is worth watching.

What is Ishares Nasdaq Biotechnology stock price?

On 2026-06-17, Ishares Nasdaq Biotechnology (IBB) stock closed at a price of $173.44.

Most Recent Experts

Jim Cramer - Mad Money

CNBC

John Zechner

J. Zechner & Assoc

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Ishares Nasdaq Biotechnology (IBB)